skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
NIHOTHER
OSTI Identifier:
1347798
Resource Type:
Journal Article
Resource Relation:
Journal Name: Bioorganic and Medicinal Chemistry; Journal Volume: 25; Journal Issue: 4
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Tan, Li, Gurbani, Deepak, Weisberg, Ellen L., Jones, Douglas S., Rao, Suman, Singer, William D., Bernard, Faviola M., Mowafy, Samar, Jenney, Annie, Du, Guangyan, Nonami, Atsushi, Griffin, James D., Lauffenburger, Douglas A., Westover, Kenneth D., Sorger, Peter K., and Gray, Nathanael S.. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. United States: N. p., 2017. Web. doi:10.1016/j.bmc.2016.11.034.
Tan, Li, Gurbani, Deepak, Weisberg, Ellen L., Jones, Douglas S., Rao, Suman, Singer, William D., Bernard, Faviola M., Mowafy, Samar, Jenney, Annie, Du, Guangyan, Nonami, Atsushi, Griffin, James D., Lauffenburger, Douglas A., Westover, Kenneth D., Sorger, Peter K., & Gray, Nathanael S.. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. United States. doi:10.1016/j.bmc.2016.11.034.
Tan, Li, Gurbani, Deepak, Weisberg, Ellen L., Jones, Douglas S., Rao, Suman, Singer, William D., Bernard, Faviola M., Mowafy, Samar, Jenney, Annie, Du, Guangyan, Nonami, Atsushi, Griffin, James D., Lauffenburger, Douglas A., Westover, Kenneth D., Sorger, Peter K., and Gray, Nathanael S.. Wed . "Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors". United States. doi:10.1016/j.bmc.2016.11.034.
@article{osti_1347798,
title = {Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors},
author = {Tan, Li and Gurbani, Deepak and Weisberg, Ellen L. and Jones, Douglas S. and Rao, Suman and Singer, William D. and Bernard, Faviola M. and Mowafy, Samar and Jenney, Annie and Du, Guangyan and Nonami, Atsushi and Griffin, James D. and Lauffenburger, Douglas A. and Westover, Kenneth D. and Sorger, Peter K. and Gray, Nathanael S.},
abstractNote = {},
doi = {10.1016/j.bmc.2016.11.034},
journal = {Bioorganic and Medicinal Chemistry},
number = 4,
volume = 25,
place = {United States},
year = {Wed Feb 01 00:00:00 EST 2017},
month = {Wed Feb 01 00:00:00 EST 2017}
}
  • Cited by 1
  • The heterodimer HIF-1α (hypoxia inducible factor)/HIF-β (also known as ARNT-aryl hydrocarbon nuclear translocator) is a key mediator of cellular response to hypoxia. The interaction between these monomer units can be modified by the action of small molecules in the binding interface between their C-terminal heterodimerization (PasB) domains. Taking advantage of the presence of several cysteine residues located in the allosteric cavity of HIF-1α PasB domain, we applied a cysteine-based reactomics “hotspot identification” strategy to locate regions of HIF-1α PasB domain critical for its interaction with ARNT. COMPOUND 5 was identified using a mass spectrometry-based primary screening strategy and was shownmore » to react specifically with Cys255 of the HIF-1α PasB domain. Biophysical characterization of the interaction between PasB domains of HIF-1α and ARNT revealed that covalent binding of COMPOUND 5 to Cys255 reduced binding affinity between HIF-1α and ARNT PasB domains approximately 10-fold. Detailed NMR structural analysis of HIF-1α-PasB-COMPOUND 5 conjugate showed significant local conformation changes in the HIF-1α associated with key residues involved in the HIF-1α/ARNT PasB domain interaction as revealed by the crystal structure of the HIF-1α/ARNT PasB heterodimer. Our screening strategy could be applied to other targets to identify pockets surrounding reactive cysteines suitable for development of small molecule modulators of protein function.« less
  • Here, we developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors. Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacologically well interrogated kinases such as p38α (MAPK14) and ABL. Further investigation of the structure–activity relationship (SAR) resulted in the identification of potent dual TAK1 and MAP4K2 inhibitors such as 1 (NG25) and 2 as well as MAP4K2 selective inhibitors such as 16more » and 17. Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacological studies in vivo. Lastly, a 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.« less
  • Here, we developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors. Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacologically well interrogated kinases such as p38α (MAPK14) and ABL. Further investigation of the structure–activity relationship (SAR) resulted in the identification of potent dual TAK1 and MAP4K2 inhibitors such as 1 (NG25) and 2 as well as MAP4K2 selective inhibitors such as 16more » and 17. Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacological studies in vivo. Lastly, a 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.« less
    Cited by 20